The AI Intelligence Platform for Peptide Biotechnology.
Track peptide companies, clinical trials, FDA events, and biotechnology research from one platform.
8
Companies tracked
9
Peptides profiled
10
Trials indexed
8
Catalysts scheduled
Trending companies
Public biotechs developing peptide therapeutics
Upcoming events
FDA catalysts and clinical readouts
Trial history
Recently completed peptide clinical trials
SURMOUNT — tirzepatide in obesity
Eli Lilly · Obesity · n = 2,539
SURPASS — tirzepatide in T2D
Eli Lilly · Type 2 Diabetes · n = 1,879
STEP — semaglutide in obesity
Novo Nordisk · Obesity · n = 1,961
SUSTAIN — semaglutide long-term outcomes
Novo Nordisk · Type 2 Diabetes · n = 1,200
Pipeline activity
Investigational peptides in active development
GIP / GLP-1 / glucagon triple agonist
Phase 3Retatrutide
Eli Lilly · Obesity, Type 2 Diabetes
GLP-1 / glucagon dual agonist
Phase 3Survodutide
Zealand Pharma · Obesity, MASH
Long-acting amylin analog
Phase 3Cagrilintide
Novo Nordisk · Obesity
GIPR antagonist / GLP-1 agonist peptide-antibody
Phase 2MariTide
Amgen · Obesity
Dual GLP-1 / GIP agonist
Phase 2VK2735
Viking Therapeutics · Obesity
Oral small-molecule GLP-1
Phase 2GSBR-1290
Structure Therapeutics · Obesity, Type 2 Diabetes
Latest research
Peer-reviewed peptide research
Data unavailable
A verified research feed is not yet connected.
We only display research pulled from cited primary sources. This feed launches once our editorial pipeline is verified end-to-end.
AI Research Assistant
Ask questions. Get cited answers.
The assistant only answers using verified sources in our database. Every response includes citations. It refuses medical, dosing, purchasing, and personalized investment questions.
$ ask
Which companies have Phase 3 GLP-1 / GIP / glucagon triagonists in obesity?
→ answer
Eli Lilly is advancing retatrutide (LY3437943), a triagonist targeting GIP, GLP-1, and glucagon receptors, in Phase 3 for obesity and type 2 diabetes.[1]
[1] clinicaltrials.gov · NCT05929066 · TRIUMPH program